BRPI0910592A2 - antagonistas de receptor 2 de somatostatina - Google Patents

antagonistas de receptor 2 de somatostatina

Info

Publication number
BRPI0910592A2
BRPI0910592A2 BRPI0910592A BRPI0910592A BRPI0910592A2 BR PI0910592 A2 BRPI0910592 A2 BR PI0910592A2 BR PI0910592 A BRPI0910592 A BR PI0910592A BR PI0910592 A BRPI0910592 A BR PI0910592A BR PI0910592 A2 BRPI0910592 A2 BR PI0910592A2
Authority
BR
Brazil
Prior art keywords
antagonists
somatostatin receptor
somatostatin
receptor
Prior art date
Application number
BRPI0910592A
Other languages
English (en)
Inventor
Helmut R Maecke
Jean Claude Reubi
Jean E F Rivier
Judit Erchegyi
Original Assignee
Salk Inst For Biological Studi
Universität Bern
Univ Hospital Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi, Universität Bern, Univ Hospital Basel filed Critical Salk Inst For Biological Studi
Publication of BRPI0910592A2 publication Critical patent/BRPI0910592A2/pt
Publication of BRPI0910592B1 publication Critical patent/BRPI0910592B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/655—Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0910592-1A 2008-04-16 2009-04-15 Antagonista de receptor 2 de somatostatina (sstr2), uso de uma composição compreendendo o mesmo, kit e composto para radioimageamento diagnóstico e para tratamento de câncer BRPI0910592B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/104,318 2008-04-16
US12/104,318 US8691761B2 (en) 2006-10-16 2008-04-16 Somatostatin receptor 2 antagonists
PCT/US2009/040672 WO2009129311A2 (en) 2008-04-16 2009-04-15 Somatostatin receptor 2 antagonists

Publications (2)

Publication Number Publication Date
BRPI0910592A2 true BRPI0910592A2 (pt) 2015-09-22
BRPI0910592B1 BRPI0910592B1 (pt) 2021-10-19

Family

ID=41100782

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910592-1A BRPI0910592B1 (pt) 2008-04-16 2009-04-15 Antagonista de receptor 2 de somatostatina (sstr2), uso de uma composição compreendendo o mesmo, kit e composto para radioimageamento diagnóstico e para tratamento de câncer

Country Status (10)

Country Link
US (1) US8691761B2 (pt)
EP (2) EP2268667A2 (pt)
JP (2) JP2011520787A (pt)
CN (1) CN102089321B (pt)
AU (1) AU2009236211B2 (pt)
BR (1) BRPI0910592B1 (pt)
CA (1) CA2721470C (pt)
ES (1) ES2646192T3 (pt)
RU (1) RU2010146497A (pt)
WO (1) WO2009129311A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
GB201117428D0 (en) * 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
RU2528414C1 (ru) * 2013-01-25 2014-09-20 Закрытое Акционерное Общество "Фарм-Синтез" Циклический октапептид, радиофармацевтическое средство на его основе и способ применения радиофармацевтического средства для получения лекарственных (фармацевтических) средств для лечения новообразований, экспрессирующих соматостатиновые рецепторы
CA2972058C (en) 2014-01-03 2022-05-24 British Columbia Cancer Agency Branch Compositions and methods for imaging cancer
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US11279732B2 (en) 2016-02-09 2022-03-22 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same
KR20190020341A (ko) * 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
US10849955B2 (en) 2016-09-28 2020-12-01 City Of Hope Methods of treating pancreatic cancer using GPCR antagonists
JP7693317B2 (ja) * 2017-05-05 2025-06-17 センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション 二官能性キレートの薬物動態増強及びその使用
MA49398A (fr) 2017-05-05 2020-04-22 Eric Steven Burak Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
WO2019222851A1 (en) 2018-05-23 2019-11-28 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
TW202015744A (zh) * 2018-06-21 2020-05-01 法商艾普森藥品公司 用於放射性醫藥之含有體抑素類似物之組成物
TW202547563A (zh) * 2018-06-21 2025-12-16 德商愛利穆治療有限公司 用於放射性醫藥之含有體抑素類似物之組成物
KR20210110834A (ko) 2018-12-18 2021-09-09 프로빈셜 헬스 서비시즈 오쏘리티 이중 방식의 18f-표지된 테라노스틱 화합물 및 그 용도
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
CA3144094A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
IL301342A (en) 2020-10-21 2023-05-01 Provincial Health Services Authority Novel CXCR4-targeting compounds
DE102021111452B3 (de) 2021-05-04 2022-07-28 Positron Precision GmbH Markierungsvorläufer und Radiotracer für neuroendokrine Theranostik
EP4232097A1 (en) * 2021-09-30 2023-08-30 Universität Basel [161Tb]-BASED RADIOPEPTIDES
US20260053958A1 (en) * 2022-08-30 2026-02-26 Grafton Therapeutics Sàrl Halogenated somatostatin analogs with multiple somatostatin receptor subtype selectivity
WO2024064969A2 (en) 2022-09-23 2024-03-28 Nuclidium Ag High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
CN119708199A (zh) * 2023-09-27 2025-03-28 钱杭江医药科技(嘉兴)有限公司 生长抑素肽类类似物、螯合物及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3904594A (en) 1973-07-02 1975-09-09 Salk Inst For Biological Studi Somatostatin and acylated des-(ala' 1', gly' 2') derivatives thereof
US4372884A (en) 1975-08-06 1983-02-08 The Salk Institute For Biological Studies Pharmaceutically active peptides
US4428942A (en) 1982-05-17 1984-01-31 The Salk Institute For Biological Studies Analogs of somatostatin
US4725577A (en) 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US5776894A (en) * 1988-12-05 1998-07-07 Novartis Ag Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
US5590656A (en) 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
CA2183421A1 (en) 1994-02-18 1995-08-24 John Mertens Labelled peptide compounds
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5708135A (en) 1995-09-29 1998-01-13 Biomeasure Incorporated Cyclic peptide analogs of somatostatin
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6262229B1 (en) 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
IL130166A0 (en) 1996-12-04 2000-06-01 Sod Conseils Rech Applic Somatostatin antagonists
US5925618A (en) 1997-03-06 1999-07-20 American Cyanamid Company Peptides useful as somatostatin antagonists
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
CN1124281C (zh) * 1999-02-13 2003-10-15 中国人民解放军军事医学科学院基础医学研究所 生长抑素多肽类似物及其应用
US6579967B1 (en) 1999-12-14 2003-06-17 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
AU3290302A (en) 2000-10-20 2002-04-29 Univ Tulane Urotensin-ii agonists and antagonists
RU2263678C2 (ru) 2001-03-08 2005-11-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
US7019109B2 (en) 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs
EP1283216A1 (en) 2001-08-10 2003-02-12 Mallinckrodt Inc. Somatostatin analogues binding to all somatostatin receptor subtypes and their use
PL369336A1 (en) 2001-09-21 2005-04-18 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
WO2004009614A2 (en) 2002-07-24 2004-01-29 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
DK1603598T3 (da) 2003-03-19 2009-01-26 Univ Bern Radiomærkede konjugater baseret på substans P og anvendelser heraf
PL2383289T3 (pl) 2006-10-16 2015-03-31 Salk Inst Biological Studies Antagoniści somatostatyny selektywni względem receptora (SSTR2)

Also Published As

Publication number Publication date
CA2721470A1 (en) 2009-10-22
CN102089321B (zh) 2017-03-22
EP2268667A2 (en) 2011-01-05
US8691761B2 (en) 2014-04-08
JP2011520787A (ja) 2011-07-21
ES2646192T3 (es) 2017-12-12
EP2801582A1 (en) 2014-11-12
US20080299040A1 (en) 2008-12-04
BRPI0910592B1 (pt) 2021-10-19
JP2014129382A (ja) 2014-07-10
CA2721470C (en) 2017-03-07
AU2009236211B2 (en) 2013-12-19
WO2009129311A3 (en) 2010-07-22
RU2010146497A (ru) 2012-05-27
AU2009236211A1 (en) 2009-10-22
EP2801582B1 (en) 2017-09-06
WO2009129311A2 (en) 2009-10-22
CN102089321A (zh) 2011-06-08

Similar Documents

Publication Publication Date Title
FR22C1020I1 (fr) Antagonistes de c5ar
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
EP1981902A4 (en) ANTAGONISTS OF NOGO RECEPTORS
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0923512A2 (pt) antagonistas de receptores de ácido lisofosfatídico
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
BRPI0921696A2 (pt) Antagonistas do receptor do tipo toll 3
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
DK2081951T3 (da) Progesteron-receptorantagonister
DK2009992T3 (da) Il-8 receptor-antagonister
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0810926A2 (pt) Antagonista de crig
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
EP2170064A4 (en) 6,5-pyrrolopiperidine tachykinin receptor antagonists
BRPI0918004A2 (pt) antagonistas de glucagon
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
IL209264A0 (en) Heteroaromatic monoamides as orexinin receptor antagonists
DK2121630T3 (da) Hurtigt dissocierende dopamin-2-receptor-antagonister
BRPI0720078A2 (pt) 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
BRPI0820633A2 (pt) antagonistas de receptores de il-4 muteína modificada
ATE547407T1 (de) Alkylthiopyrimidine als crth2-antagonisten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.